Clinical significance of CA 72-4 as a serological tumor-associated marker

Close metadata

Recommended articles:

Morphological and molecular genetic features of gastric cancer. P.A. Herzen Journal of Oncology. 2024;(3):79-84

Conversion surgery for gastric cancer with limited peritoneal carcinomatosis. P.A. Herzen Journal of Oncology. 2024;(4):5-10

Risk groups model in colorectal cancer screening. Russian Journal of Preventive Medicine. 2024;(5):12-22

Influence of intestinal microbiota on cardiovascular atherosclerotic diseases and colorectal cancer in elderly patients. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):30-36

Results of using endoscopic stenting of the gastric outlet and duodenum with metal self-expanding stents. Endoscopic Surgery. 2024;(3):11-20

Palliative large-bowel decompression for colorectal obstruction in patients with unresectable locally advanced cancer and carcinomatosis. Endoscopic Surgery. 2024;(3):21-28

Double-tract reconstruction after gastrectomy for gastric cancer in patients with concomitant cardiovascular diseases. Pirogov Russian Journal of Surgery. 2024;(6):58-69

The impact of endoscopy in upper gastrointestinal tract cancer screening programs. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):79-88

Primary prevention of colorectal cancer and technologies for its implementation into practical health care. Russian Journal of Preventive Medicine. 2024;(6):111-117

The role of the Kyoto classification in the endoscopic diagnosis of gastritis associated with Helicobacter pylori infection. Endoscopic Surgery. 2024;(4):65-72

The serological tumor-associated marker CA 72-4 is traditionally positioned as a marker for mucinous ovarian cancer and gastric cancer, being considered relatively highly tumor-specific. However, in clinical practice, some of the examinees without cancer processes were found to have an increase in the serum levels of the marker (by 2.0—2.5 times higher than the upper limit of the normal range). This served as a basis for revising the data available in the literature regarding this marker. The review presents the history of discovery of CA 72-4, its structure, cellular functions, and tissue and serum expression in different physiological states, in non-tumor pathological processes, and in benign and malignant tumors.

Keywords:

CA 72-4

ovarian cancer

gastric cancer

colorectal cancer

Authors:

Sergeeva N.S.

Russian University of Peoples' Friendship

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Solokhina M.P.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Alentov I.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

SPIN RSCI: 1759-8101
Scopus AuthorID: 6602709853
ResearcherID: K-1445-2014
ORCID: 0000-0001-8784-8415

List of references:

Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci. 1981;78(5):3199-3203. https://doi.org/10.1073/pnas.78.5.3199
Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986;46(2):850-857.
Gero EJ, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P. CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients. J Clin Lab Anal. 1989;3(6):360-369. https://doi.org/10.1002/jcla.1860030609
Jin H, Wang X, Bing TB, Gao P, Lin JM, Liang SX. Microplate chemiluminescence enzyme immunoassay for the quantitative evaluation of carbohydrate antigen 72-4 in human serum. Chin Sci Bull. 2008;53(19):2958-2963. https://doi.org/10.1007/s11434-008-0428-9
Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res.1988;48(23):6811-6818.
Katari RS, Fernsten PD, Schlom J. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res. 1990;50(16):4885-4890.
Devine PL, McKenzie IF. Mucins: structure, function, and associations with malignancy. Bioessays. 1992;14(9):619-625. https://doi.org/10.1002/bies.950140909
Laskarin G, Redzovic A, Vlastelic I, Haller H, Medancic SS, Solinas G, Rukavina D. Tumor-associated glycoprotein (TAG-72) is a natural ligand for the C-type lectin-like domain that induces anti-inflammatory orientation of early pregnancy decidual CD1a+ dendritic cells. J Reprod Immunol. 2011;88(1):12-23. https://doi.org/10.1016/j.jri.2010.10.001
Kristofic I, Redzovic A, Laskarin G, Eminovic S, Haller H, Rukavina D. Role of tumor-associated glycoprotein-72 in the progression of endometrial adenocarcinoma: a proposed study. Med Hypotheses. 2015;84(5):413-416. https://doi.org/10.1016/j.mehy.2014.10.017
Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986;46(6):3118-3124.
Stanick D, Schuss A, Mishriki Y, Chao S, Thor A, Lundy J. Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas. Cancer Investig. 1988;6(3):279-287. https://doi.org/10.3109/07357908809080650
Guzman J, Izumi T, Nagai S, Costabel U. Immunocytochemical characterization of isolated human type II pneumocytes. Acta Cytol. 1994;38(4):539-542.
Bartolazzi A, Mottolese M, Vocaturo A, Bigotti A, Vocaturo G, Atlante G, Prat M, Natali PG. Expression of CAR-3 and TAG-72 macromolecules in normal and transformed endometrium: potential diagnostic application in postmenopausal patients. Cancer Res. 1991;51(11):3001-3005.
Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, Smith L, Davis JS, Remmenga SW, Batra SK. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 2007;251(2):247-257. https://doi.org/10.1016/j.canlet.2006.11.025
Galietta A, Pizzi C, Pettinato G, Limite G, Sgambato A, Lamberti M, Muraro R, Formisano C, Pensabene M, Bianco AR, Mariani-Costantini R, Contegiacomo A. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype. Oncol Rep. 2002;9(1):135-140. https://doi.org/10.3892/or.9.1.135
Karan D, Johansson SL, Lin MF, Batra SK. Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas. Oncol Rep. 2001;8(5):1123-1126. https://doi.org/10.3892/or.8.5.1123
Wang D, Zhang Y, Li X, Cui J, Wang S. A preliminary study on the expression of tumor-associated glycoprotein-72 in human gliomas. Med Oncol. 2012;29(3):2027-31. https://doi.org/10.1007/s12032-011-0027-5
Szekanecz E, Szucs G, Szekanecz Z, Tarr T, Antal-Szalmás P, Szamosi S, Szántó J, Kiss E. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun. 2008;31(4):372-376. https://doi.org/10.1016/j.jaut.2008.08.008
Arkhipkin AA, Lyang OV, Kochetov AG. The fetal proteins in prognosis of development of pneumonia in patients with ischemic stroke. Klinicheskaya laboratornaya diagnostika. 2014;59(12):13-16. (In Russ.)
Lessey BA, Pindzola JA. Tumor-associated glycoprotein (TAG-72) in endometriotic implants. J Clin Endocrinol Metab. 1993;76(4):1075-1079. https://doi.org/10.1210/jcem.76.4.7682561
Imai A, Horibe S, Takagi A, Takagi H, Tamaya T. Drastic elevation of serum CA125, CA72-4 and CA19-9 levels during menses in a patient with probable endometriosis. Eur J Obstet Gynecol Reprod Biol. 1998;78(1):79-81. https://doi.org/10.1016/s0301-2115(98)00003-7
Shang X, Song C, Du X, Shao H, Xu D, Wang X. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. Saudi Med J. 2017;38(2):204-208. https://doi.org/10.15537/smj.2017.2.15649
Parisi L, Gini E, Baci D, Tremolati M, Fanuli M, Bassani B, Farronato G, Bruno A, Mortara L. Macrophage polarization in chronic inflammatory diseases: killers or builders? J Immunol Res. 2018;2018:8917804. https://doi.org/10.1155/2018/8917804
Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol. 2015;6:602. https://doi.org/10.3389/fimmu.2015.00602
Schwartz AM, Silverberg SG, Fu YS, Nozawa S, Huang S, Tsukasaki K, Williams KR. Use of monoclonal antibodies MSN-1 and B72.3 in the prediction of the natural history of endometrial hyperplasia. Int J Gynecol Pathol. 1993;12(3):253-258. https://doi.org/10.1097/00004347-199307000-00009
Scambia G, Benedetti Panici P, Perrone L, Sonsini C, Giannelli S, Gallo A, Natali PG, Mancuso S. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies. Br J Cancer. 1990;62(1):147-151. https://doi.org/10.1038/bjc.1990.248
Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friese K, Stieber P, Burges A. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med. 2009;47(5):537-542. https://doi.org/10.1515/CCLM.2009.134
Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M. Evaluation of a novel ELISA for the tumorassociated antigen CA 72-4 in patients with ovarian cancer. Future Sci OA. 2016;2(4):FSO145. https://doi.org/10.4155/fsoa-2016-0040
Bayer B, Meier W, Steiber P, Albiez M, Eirmann W, Fateh-Moghadam A. Significance of CA72-4 in the diagnosis of ovarian cancer. In: Klapdor R, ed. Recent results in tumor therapy and diagnosis. Munich: Zuckschwedt-Verlag, 1990;111-112.
Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian patients. Gynecol Oncol. 1993;48:148-154. https://doi.org/10.1006/gyno.1993.1026
Fayed ST, Ahmad SM, Kassim SK, Khalifa A. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers. 1998;14(3):155-160. https://doi.org/10.1155/1998/738321
Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012;33(5):1335-1339. https://doi.org/10.1007/s13277-012-0381-8
Anastasi E, Manganaro L, Granato T, Panici PB, Frati L, Porpora MG. Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer? Dis Markers. 2013;35(5):331-335. https://doi.org/10.1155/2013/984641
Vlahos NF, Economopoulos KP, Fotiou S. Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract Res Clin Obstet Gynaecol. 2010;24(1):39-50. https://doi.org/10.1016/j.bpobgyn.2009.08.004
Zygouris D, Leontara V, Makris GM, Chrelias C, Trakakis E, Christodoulaki Ch, Panagopoulos P. Endometrioid ovarian cancer arising from an endometriotic cyst in a young patient. Eur J Gynaecol Oncol. 2012;33(3):324-325.
Terry KL, Schock H, Fortner RT, Hüsing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016;22(18):4664-4675. https://doi.org/10.1158/1078-0432.CCR-16-0316
Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Cianetti A, Vannini P. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol. 1998;124(8):450-455. https://doi.org/10.1007/s004320050198
Sun Zh, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:397. https://doi.org/10.1186/1477-7819-12-397
Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumor Biol. 2001;22(5):318-322. https://doi.org/10.1159/000050633
Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008;25(10):1075-1084. https://doi.org/10.1007/s12325-008-0100-4
Ayude D, Rodríguez-Berrocal FJ, Ayude J, Blanco-Prieto S, Vázquez-Iglesias L, Vázquez-Cedeira M, Páez de la Cadena M. Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer. BMC Cancer. 2013;13:543. https://doi.org/10.1186/1471-2407-13-543

Close metadata